Bridgefront Capital’s Immunovant IMVT Stock Holding History

Bridgefront Capital’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$543K	Sell	14,085 -13,724	-49%	-$418K	0.14%	240
2026 Q1	$691K	Buy	+27,809	New	+$720K	0.17%	201
2025 Q4	–	Sell	-13,654	Closed	-$220K	–	648
2025 Q3	$220K	Sell	13,654 -7,067	-34%	-$114K	0.06%	495
2025 Q2	$332K	Sell	20,721 -15,338	-43%	-$232K	0.09%	399
2025 Q1	$616K	Buy	+36,059	New	+$754K	0.18%	198
2022 Q3	–	Sell	-15,649	Closed	-$61K	–	385
2022 Q2	$61K	Sell	15,649 -3,353	-18%	-$14.5K	0.07%	280
2022 Q1	$105K	Buy	+19,002	New	+$118K	0.13%	232
2021 Q3	–	Sell	-13,612	Closed	-$144K	–	506
2021 Q2	$144K	Buy	+13,612	New	+$190K	0.05%	535

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bridgefront Capital's IMVT Position: Q2 2026 in Review

Bridgefront Capital reduced its Immunovant (IMVT) stake by 49% in Q2 2026, selling an estimated $418K and leaving 14,085 shares worth $543K. The position accounts for 0.14% of the portfolio, ranked #240.

Bridgefront Capital first reported a position in IMVT in Q2 2021 and has held it in 8 quarters since. The position peaked at $691K in Q1 2026. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Bridgefront Capital held 14,085 shares of Immunovant worth $543K as of Q2 2026.
Bridgefront Capital sold 13,724 Immunovant shares in Q2 2026, an estimated $418K.
Immunovant made up 0.14% of Bridgefront Capital's portfolio in Q2 2026, its #240 holding.
Bridgefront Capital first reported a position in Immunovant in Q2 2021 and has held it in 8 quarters since.
Bridgefront Capital's Immunovant position peaked at $691K in Q1 2026.
226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.